A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Celiac Disease, Coeliac Disease

In brief

The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)

Key facts

Study ID
NCT06001177
Run by
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
People needed
55
Starts
2023-12-13
Expected to finish
2025-01-13
Last updated by the study team
2025-12-18

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.